Nuowei Technology

Beijing Nuowei Technology is a clinical-stage biotechnology company dedicated to the development of innovative immune cell therapies for solid tumors. The company's core technology is the proprietary STAR-T (Synthetic T cell Antigen Receptor) platform, which aims to overcome the limitations of traditional CAR-T therapies in treating solid malignancies. Nuowei's lead program, NWT-01, targets Glypican-3 (GPC3) and is currently undergoing clinical evaluation for hepatocellular carcinoma. Based in Beijing, the company maintains integrated capabilities spanning from early-stage discovery to GMP-compliant manufacturing. Through its advanced engineering approach, Nuowei seeks to provide effective treatment options for patients with high-unmet-need gastrointestinal and other solid cancers.